title: [The expression and clinical significance of EphA2 and E-cadherin in papillary thyroid carcinoma].
abstract: OBJECTIVE
  To investigate the expression and clinical significance of EphA2 and E cadherin proteins in papillary thyroid carcinoma tissues, and to explore the relationship between them.
  
  
  METHODS
  Using immunohistochemical SP/PV method, we detected the expression of EphA2 and E cadherin in tumors of 43 papillary thyroid carcinomas, 11 thyroid adenoma and 10 normal thyroid tissues, then studied their relationships with clinic pathological factors.
  
  
  RESULTS
  The total positive rates of EphA2 and E cadherin expression were 58. 14% and 32. 56% in papillary thyroid carcinoma tissues, 18. 18% and 81. 81% in thyroid adenoma.tissues and they were 10. 00% and 100. 00% in normal thyroid tissues respectively. The positive expression of EphA2 in carcinoma tissues was higher than in the thyroid adenoma tissues and normal thyroid tissues (P<0. 05) and the positive expression of E cadherin in carcinoma tissues was lower than that in the thyroid adenoma tissues and normal thyroid tissues (P<0. 05). The positive expression of EphA2 and E cadherin was associated with lymph node metastasis and histological grade (P<0. 05), but it was not associated with all the clinic-pathological factors including age, sex and the tumor size (P>0. 05). In papillary thyroid carcinoma tissues, the expression of EphA2 was negatively correlated with the expression of E cadherin protein (r= -0. 416, P<0. 01).
  
  
  CONCLUSIONS
  EphA2 and E cadherin may be involved in carcinogenesis and development of papillary thyroid carcinoma.
authors.forename: Yan
authors.initials: Y
authors.lastname: Liu
authors.forename: Yuhua
authors.initials: Y
authors.lastname: Miao
authors.forename: Xiaoming
authors.initials: X
authors.lastname: Li
mesh_terms: D000236:Adenoma / Q000378:metabolism / Q000473:pathology*; D015703:Antigens, CD; D015820:Cadherins / Q000378:metabolism*; D002277:Carcinoma / Q000378:metabolism / Q000473:pathology*; D002291:Carcinoma, Papillary; D006801:Humans; D008207:Lymphatic Metastasis; D036104:Receptor, EphA2 / Q000378:metabolism*; D000077273:Thyroid Cancer, Papillary; D013961:Thyroid Gland / Q000378:metabolism; D013964:Thyroid Neoplasms / Q000378:metabolism / Q000473:pathology*
chemical_list: D015703:Antigens, CD; C513384:CDH1 protein, human; D015820:Cadherins; D036104:Receptor, EphA2